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Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer related mortality world-wide and ther-
apeutic options are very limited. A new therapeutic
approach is the adoptive T cell therapy of HCC. Glypican-3
(GPC3) as a tumour associated antigen is expressed in up
to 60% of all HCC but not in healthy human liver tissue.
Therefore, our goal is to generate cytotoxic T lymphocytes
(CTL), which are capable of recognizing and eliminating
GPC3-expressing tumor cells.
Immunodominant epitopes for GPC3 have not been
described yet. In this study we used Ultra Nano HPLC
coupled on-line to the Q Exactive mass spectrometer to
obtain a comprehensive HLA class I peptidome from a
GPC3 and HLA-A2 positive hepatoma cell line. The
resulting data were analysed using the MaxQuant bioin-
formatics platform. Two HLA-A2 bound GPC3 peptides
could be identified, later on referred to as GPC3-P1 and
GPC3-P2. These results enable us to target GPC3 epitopes
that are presented on GPC3 positive HCC cells.
To isolate tumour reactive high avidity T cells, an allo-
restricted stimulation approach was used. For stimulation of
naïve T cells, autologous dendritic cells were co-transfected
with GPC3 and HLA-A2 RNA and used as antigen present-
ing cells. T cells from the naïve T cell repertoire of HLA-A2
negative donors were co-cultured with and expanded on
these HLA-A2+ GPC3+ DCs. After two weeks, MHC strep-
tamer-positive CD8+ T cells specific for both targeted
GPC3 epitopes were detected (<1%). We were able to
enrich these cell populations further to 35% GPC3-P1- and
57% GPC3-P2-MHC streptamer-positive T cell lines and
grew T cell clones from them. In a co-culture with GPC3-
P1/ -P2 peptide loaded T2 cells we identified T cell clones
displaying specific effector function by IFNg secretion.
Functional T cell clones showed strong GPC3 MHC strep-
tamer binding.
We have cloned the first T cell receptors (TCR) to either
GPC3 peptide from these T cell clones. T cells engrafted
with the GPC3 specific TCRs showed strong GPC3 MHC
streptamer binding. When co-cultured with GPC3 peptide
loaded target cells or a GPC3 expressing hepatoma cell
line (HepG2), GPC3 TCR transduced T cells secreted
IFNg. Furthermore cytotoxicity was observed by killing of
up to 60% of HepG2 cells. GPC3-directed T cell therapy
shows great promise for the treatment of HCC.
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